{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=55", "query": { "intervention": "Placebo", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 4225, "total_pages": 423, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=54&page_size=10" }, "source": "local", "last_synced_at": "2026-11-04T21:43:36.459Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06500702", "title": "A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Segmental Glomerulosclerosis", "Glomerulonephritis Minimal Lesion" ], "interventions": [ { "name": "brivekimig", "type": "DRUG" }, { "name": "frexalimab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "rilzabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "16 Years to 75 Years" }, "enrollment_count": 84, "start_date": "2024-12-19", "completion_date": "2028-02-16", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-03T23:15:59.774Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06500702" }, { "nct_id": "NCT06484075", "title": "Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Alcohol Use Disorder (AUD)", "Healthy Volunteers" ], "interventions": [ { "name": "PET/CT Scanner", "type": "DEVICE" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Siemens 3T PRISMA MR Scanner", "type": "DEVICE" }, { "name": "Suvorexant", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 180, "start_date": "2024-11-21", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T09:36:00.596Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06484075" }, { "nct_id": "NCT06290141", "title": "A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyneuropathy" ], "interventions": [ { "name": "IVIg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "riliprubart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2024-08-21", "completion_date": "2029-01-12", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-04T21:43:36.459Z", "location_count": 32, "location_summary": "Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06290141" }, { "nct_id": "NCT06085716", "title": "Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Fatigue", "Metastatic Cancers" ], "interventions": [ { "name": "Open Label Placebo", "type": "DRUG" }, { "name": "Psychoeducational Intervention", "type": "BEHAVIORAL" }, { "name": "Psychoeducational Intervention+Placebo", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2024-02-16", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T15:35:54.518Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06085716" }, { "nct_id": "NCT06012240", "title": "A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "63 Years", "sex": "ALL", "summary": "12 Years to 63 Years" }, "enrollment_count": 1500, "start_date": "2023-10-11", "completion_date": "2030-04", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-28T01:22:15.751Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06012240" }, { "nct_id": "NCT05975580", "title": "Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "Phentermine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 120, "start_date": "2023-08-29", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T15:29:04.846Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05975580" }, { "nct_id": "NCT05421858", "title": "A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidemia", "Candidiasis, Invasive" ], "interventions": [ { "name": "Caspofungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Fosmanogepix", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-12-11", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-27T13:08:20.393Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05421858" }, { "nct_id": "NCT05367245", "title": "Ca-Mg Butyrate in Gulf War Illness", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Fatigue", "Gulf War Illness", "Neurocognitive Dysfunction" ], "interventions": [ { "name": "Cal-Mag Butyrate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 120, "start_date": "2024-01-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T22:15:51.533Z", "location_count": 3, "location_summary": "Long Beach, California • Miami, Florida • Salt Lake City, Utah", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05367245" }, { "nct_id": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Astrocytoma, Grade IV", "Astrocytoma, IDH-Mutant, Grade 2", "Astrocytoma, IDH-Mutant, Grade 3", "Astrocytoma, IDH-Mutant, Grade 4", "Glioma", "IDH1-mutant Glioma", "Oligodendroglioma", "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "safusidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2023-06-05", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-19T17:40:34.021Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05303519" }, { "nct_id": "NCT04971954", "title": "Using Nicotine to Reverse Age-related Auditory Processing Deficits", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Aging", "Auditory Perceptual Impairment" ], "interventions": [ { "name": "Nicotine gum", "type": "OTHER" }, { "name": "Placebo gum", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 48, "start_date": "2022-02-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-20T09:47:10.349Z", "location_count": 2, "location_summary": "Irvine, California • San Diego, California", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971954" } ] }